Eliglustat is a substrate reduction therapy indicated for the oral treatment of patients with Gaucher disease.1 The mechanism of action of eliglustat is presented in Figure 1. For further information on eliglustat, please consult your local prescribing information.
Mechanism of action of eliglustat1,2
C-ANPROM/INT//7568; Date of preparation: September 2020
1. Sanofi Genzyme. Cerdelga® EU Summary of Product Characteristics. Last updated January 2020.
2. Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 2017; 18: 441.